PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyTargeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.Anticancer effect of xanthohumol induces growth inhibition and apoptosis of human liver cancer through NF-κB/p53-apoptosis signaling pathway.PARP inhibitors are not all equal.Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.Maintenance of genome stability by Fanconi anemia proteins.HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cellsNot so WEE: targeting G₂/M to kill mesothelioma cellsTargeting the ATR-CHK1 Axis in Cancer TherapyThe emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.ATR/CHK1 inhibitors and cancer therapy.Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.Cytotoxicity of Air Pollutant 9,10-Phenanthrenequinone: Role of Reactive Oxygen Species and Redox Signaling.
P2860
Q26745686-ECE831E3-440E-471D-A0A8-401719320734Q34055827-9455B779-5823-4BFA-9838-3446F29705BEQ34062570-403D96C9-5AB3-450E-9827-A226EE0AB5C7Q36399470-9097FEF3-8646-4F72-AE82-C25022FDF112Q37589215-9F3CE86E-E206-483F-BC83-A48C08BD7B32Q37603936-FB9DA325-5526-4F3C-B4FF-55057C164C4DQ37658498-6D3FAF1F-291F-4CF8-B994-BCF476C8F713Q37683049-F9E31E34-694A-4398-9E5F-F0479783D8CCQ38662374-1E2552DF-584A-42C5-A68A-236C372384B4Q38817102-2ED5EE9F-2B91-491E-BF28-303175020827Q39190147-440D3A10-1F1B-4AEE-AD1D-489573A7A659Q41466400-4CBEB855-6C81-48C1-903F-1B8F1DD2D6EAQ47130816-E0195C88-2CFE-441B-8FE1-1DCEE873612DQ47622968-D93D2A77-7F62-47D6-8AEA-F96BB638F859Q48534871-7693C1BD-D76B-47A6-BE69-2136BC17C222Q55500290-2440ED74-0F30-490B-851B-4CE73BB2660E
P2860
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
PARP and CHK inhibitors intera ...... ath in mammary carcinoma cells
@en
type
label
PARP and CHK inhibitors intera ...... ath in mammary carcinoma cells
@en
prefLabel
PARP and CHK inhibitors intera ...... ath in mammary carcinoma cells
@en
P2093
P2860
P356
P1476
PARP and CHK inhibitors intera ...... ath in mammary carcinoma cells
@en
P2093
Laurence Booth
Nichola Cruickshanks
Steven Grant
Thomas Ridder
P2860
P304
P356
10.4161/CBT.24424
P50
P577
2013-05-01T00:00:00Z